title: New and improved glucocorticoid receptor ligands.
abstract: The therapeutic and prophylactic use of glucocorticoids is widespread due to their powerful anti-inflammatory, antiproliferative and immunomodulatory activity. However, long-term use of these drugs can result in severe dose-limiting side effects. One of the most critical and debilitating side effects is osteoporosis, which leads to increased risk of fractures. Glucocorticoids damage bone through several different mechanisms. The search for novel glucocorticoids that have reduced side effects in bone and other tissues is being driven by the identification of new mechanisms of action of the glucocorticoid receptor. This may facilitate the detection of new, safer therapies with efficacies equivalent to currently prescribed steroids.
authors.affiliation: Department of Molecular and Cell Biology, Ligand Pharmaceuticals, San Diego, CA 92121, USA.
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Miner
authors.forename: Mei Hua
authors.initials: MH
authors.lastname: Hong
authors.forename: Andrés
authors.initials: A
authors.lastname: Negro-Vilar
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008024:Ligands; D011965:Receptors, Glucocorticoid / Q000378:metabolism*
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D007166:Immunosuppressive Agents; D008024:Ligands; D011965:Receptors, Glucocorticoid